Antibiotic Resistance Industry Overview
The global antibiotic resistance market size is estimated to reach USD 12.07 billion by 2025. According to a new report by Grand View Research, Inc., it is anticipated to post a CAGR of 5.6% during the forecast period. Rising burden of antibiotic-resistant infections and emergence of multi-drug resistant pathogens has been driving the market.
Antibiotic Resistance Market Segmentation
Grand View Research has segmented the global antibiotic resistance market on the basis of disease, pathogen type, drug class, and region:
Based on the Disease Insights, the market is segmented into Complicated Urinary Tract Infection (cUTI), Complicated Intra-Abdominal Infections (cIAI), Blood Stream Infections (BSI), Clostridium difficile infections (CDI), Acute Bacterial Skin and Skin Structure Infections (ABSSSI), Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP) , Community Acquired Bacterial Pneumonia (CABP).
- The market has been categorized into cUTI, cIAI, BSI, CDI, ABSSSI, HABP/VABP, and CABP. cUTI represented the largest segment in the market in 2017 owing to high overall treatment cost and limited treatment alternatives for Gram-negative pathogens, which account for majority of infection cases.
- Antibiotic-resistant Gram-positive bacteria account for a larger number of infections by volume. However, due to availability of multiple treatment options including branded and generics drugs, the overall cost of therapy remains lower when compared with Gram-negative infections.
- Among gram-positive infections, MRSA accounted for the highest market share, being the primary causative pathogen for growing ABSSSI burden across the globe. The ABSSSI segment is projected to command a sizeable share in the antibiotic resistance market throughout the forecast period.
Based on the Pathogen Insights, the market is segmented into Acinetobacter baumannii (Carbapenem-Resistant), Pseudomonas aeruginosa (Carbapenem-Resistant), Staphylococcus Aureus, E. coli/K. pneumoniae (Carbapenem-Resistant), Streptococcus pneumoniae (Penicillin-Non-Susceptible), Clostridium difficile (Cephalosporin-Resistant, Tetracycline-Resistant), Enterococcus faecium (Vancomycin-Resistant), Haemophilus Influenzae (Ampicillin-Resistant).
- Infections due to K. pneumoniae pathogens that are carbapenem-resistant and ESBL-producing held the largest share in 2017. These infections pose treatment challenges for physicians due to high resistance to current treatment alternatives.
- These infections although fewer in terms of number of cases in comparison to Gram positive pathogens, they impose a high cost burden as physicians are increasingly shifting towards novel antibiotics such as Allergan’s Avycaz and Melinta Therapeutics’ Vabomere. CDI, on the other hand, is anticipated to register the highest CAGR during the forecast period.
Based on the Drug Class Insights, the market is segmented into Oxazolidinones, Lipoglycopeptides, Tetracyclines, Cephalosporins, Combination, Others.
- Lipoglycopeptides are likely to command 17.0% of the overall market revenue by 2025.
- The combination therapies segment, which comprises fixed dose combinations of beta lactams and beta lactamase inhibitors, is poised to experience the highest growth during the forecast period. High use of these therapies for gram negative infections that have limited treatment options is contributing to the growth of the segment.
Antibiotic Resistance Regional Outlook
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa (MEA)
Key Companies Profile & Market Share Insights
This market has fewer pharmaceutical companies entering the space, while the number of biotech companies such as Achaogen and Nabriva Therapeutics is higher. In addition, companies in the market target for higher market share through indication extension and geographic expansion strategies.
Some prominent players in the global antibiotic resistance market include
- Achaogen, Inc.
- Basilea Pharmaceutica Ltd.
- Melinta Therapeutics
- Tetraphase Pharmaceuticals, Inc.
- Theravance Biopharma, Inc.
- Wockhardt therapeutics
- Entasis Therapeutics
- PARATEK therapeutics
- Seres Therapeutics, Inc.
Order a free sample PDF of the Antibiotic Resistance Market Intelligence Study, published by Grand View Research.
About Grand View Research
Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research Helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc.
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@grandviewresearch.com
Web: https://www.grandviewresearch.com
Antibiotic Resistance Industry Overview
The global antibiotic resistance market size is estimated to reach USD 12.07 billion by 2025. According to a new report by Grand View Research, Inc., it is anticipated to post a CAGR of 5.6% during the forecast period. Rising burden of antibiotic-resistant infections and emergence of multi-drug resistant pathogens has been driving the market.
Antibiotic Resistance Market Segmentation
Grand View Research has segmented the global antibiotic resistance market on the basis of disease, pathogen type, drug class, and region:
Based on the Disease Insights, the market is segmented into Complicated Urinary Tract Infection (cUTI), Complicated Intra-Abdominal Infections (cIAI), Blood Stream Infections (BSI), Clostridium difficile infections (CDI), Acute Bacterial Skin and Skin Structure Infections (ABSSSI), Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP) , Community Acquired Bacterial Pneumonia (CABP).
- The market has been categorized into cUTI, cIAI, BSI, CDI, ABSSSI, HABP/VABP, and CABP. cUTI represented the largest segment in the market in 2017 owing to high overall treatment cost and limited treatment alternatives for Gram-negative pathogens, which account for majority of infection cases.
- Antibiotic-resistant Gram-positive bacteria account for a larger number of infections by volume. However, due to availability of multiple treatment options including branded and generics drugs, the overall cost of therapy remains lower when compared with Gram-negative infections.
- Among gram-positive infections, MRSA accounted for the highest market share, being the primary causative pathogen for growing ABSSSI burden across the globe. The ABSSSI segment is projected to command a sizeable share in the antibiotic resistance market throughout the forecast period.
Based on the Pathogen Insights, the market is segmented into Acinetobacter baumannii (Carbapenem-Resistant), Pseudomonas aeruginosa (Carbapenem-Resistant), Staphylococcus Aureus, E. coli/K. pneumoniae (Carbapenem-Resistant), Streptococcus pneumoniae (Penicillin-Non-Susceptible), Clostridium difficile (Cephalosporin-Resistant, Tetracycline-Resistant), Enterococcus faecium (Vancomycin-Resistant), Haemophilus Influenzae (Ampicillin-Resistant).
- Infections due to K. pneumoniae pathogens that are carbapenem-resistant and ESBL-producing held the largest share in 2017. These infections pose treatment challenges for physicians due to high resistance to current treatment alternatives.
- These infections although fewer in terms of number of cases in comparison to Gram positive pathogens, they impose a high cost burden as physicians are increasingly shifting towards novel antibiotics such as Allergan’s Avycaz and Melinta Therapeutics’ Vabomere. CDI, on the other hand, is anticipated to register the highest CAGR during the forecast period.
Based on the Drug Class Insights, the market is segmented into Oxazolidinones, Lipoglycopeptides, Tetracyclines, Cephalosporins, Combination, Others.
- Lipoglycopeptides are likely to command 17.0% of the overall market revenue by 2025.
- The combination therapies segment, which comprises fixed dose combinations of beta lactams and beta lactamase inhibitors, is poised to experience the highest growth during the forecast period. High use of these therapies for gram negative infections that have limited treatment options is contributing to the growth of the segment.
Antibiotic Resistance Regional Outlook
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa (MEA)
Key Companies Profile & Market Share Insights
This market has fewer pharmaceutical companies entering the space, while the number of biotech companies such as Achaogen and Nabriva Therapeutics is higher. In addition, companies in the market target for higher market share through indication extension and geographic expansion strategies.
Some prominent players in the global antibiotic resistance market include
- Achaogen, Inc.
- Basilea Pharmaceutica Ltd.
- Melinta Therapeutics
- Tetraphase Pharmaceuticals, Inc.
- Theravance Biopharma, Inc.
- Wockhardt therapeutics
- Entasis Therapeutics
- PARATEK therapeutics
- Seres Therapeutics, Inc.
Order a free sample PDF of the Antibiotic Resistance Market Intelligence Study, published by Grand View Research.
About Grand View Research
Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research Helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc.
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@grandviewresearch.com
